4/29
06:33 am
gpcr
Structure Therapeutics (GPCR) was upgraded by Canaccord Genuity Group Inc. to "strong-buy".
Low
Report
Structure Therapeutics (GPCR) was upgraded by Canaccord Genuity Group Inc. to "strong-buy".
4/28
07:24 am
gpcr
FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States
Medium
Report
FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States
4/27
04:05 pm
gpcr
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Medium
Report
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
4/27
08:00 am
gpcr
Structure Therapeutics (GPCR) was given a new $101.00 price target by Canaccord Genuity Group Inc..
Medium
Report
Structure Therapeutics (GPCR) was given a new $101.00 price target by Canaccord Genuity Group Inc..
4/23
06:02 am
gpcr
Structure Therapeutics (GPCR) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Low
Report
Structure Therapeutics (GPCR) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
4/18
11:43 am
gpcr
3 Ways to Invest in the Growing GLP-1 Weight Loss Market [Yahoo! Finance]
Medium
Report
3 Ways to Invest in the Growing GLP-1 Weight Loss Market [Yahoo! Finance]
4/18
01:00 am
gpcr
Medium
Report
4/14
04:18 pm
gpcr
Structure Therapeutics appoints Matthew Lang as chief operating officer [Seeking Alpha]
Low
Report
Structure Therapeutics appoints Matthew Lang as chief operating officer [Seeking Alpha]
4/14
04:05 pm
gpcr
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Low
Report
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
4/8
04:16 pm
gpcr
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat [Seeking Alpha]
Low
Report
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat [Seeking Alpha]
3/29
05:16 pm
gpcr
Structure Therapeutics Phase 2 Obesity Data Shifts Focus To Phase 3 [Yahoo! Finance]
Medium
Report
Structure Therapeutics Phase 2 Obesity Data Shifts Focus To Phase 3 [Yahoo! Finance]
3/28
01:05 am
gpcr
Medium
Report
3/26
09:00 am
gpcr
Structure Therapeutics (GPCR) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
Medium
Report
Structure Therapeutics (GPCR) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
3/23
11:13 am
gpcr
Structure Therapeutics CEO on the company's oral GLP-1 opportunity [CNBC]
Medium
Report
Structure Therapeutics CEO on the company's oral GLP-1 opportunity [CNBC]
3/22
04:37 pm
gpcr
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges [Yahoo! Finance]
Low
Report
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges [Yahoo! Finance]
3/18
12:30 am
gpcr
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]
Medium
Report
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]
3/17
01:11 pm
gpcr
Structure Therapeutics (GPCR) was given a new $145.00 price target by BMO Capital Markets. They now have an "outperform" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) was given a new $145.00 price target by BMO Capital Markets. They now have an "outperform" rating on the stock.
3/17
07:48 am
gpcr
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]
Low
Report
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]
3/16
02:12 pm
gpcr
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.
3/16
12:35 pm
gpcr
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]
Medium
Report
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]
3/16
12:23 pm
gpcr
Structure Therapeutics (GPCR) had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a "buy" rating on the stock.
3/16
12:08 pm
gpcr
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by Leerink Partners.
3/16
07:08 am
gpcr
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron [Yahoo! Finance]
Medium
Report
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron [Yahoo! Finance]
3/16
07:00 am
gpcr
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Medium
Report
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
3/2
08:56 am
gpcr
Structure Therapeutics (GPCR) had its price target raised by HC Wainwright from $90.00 to $114.00. They now have a "buy" rating on the stock.
Low
Report
Structure Therapeutics (GPCR) had its price target raised by HC Wainwright from $90.00 to $114.00. They now have a "buy" rating on the stock.